The Myeloma Trial Finder lists clinical trials which are currently recruiting in the UK. If you are thinking about joining a clinical trial you should talk to your healthcare team to find out if this is a suitable option for you.
It provides information about clinical trials in the UK. Trials included are not necessarily endorsed by Myeloma UK.
Further information can be found on our website under Clinical Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder.
There are currently 23 open trials.
In 108 locations
What is a Clinical Trial?
There are currently 23 open trials
- A comparison of imaging techniques used to visualise myeloma in the bone marrow
- Understanding bone pain in myeloma
- Bortezomib, lenalidomide and dexamethasone with belantamab mafodotin in newly diagnosed myeloma patients
- Belantamab mafodotin (GSK2857916) combinations for treatment of relapsed/refractory myeloma (DREAMM-6)
- A study evaluating the standard care of relapsed/refractory myeloma patients (LocoMMotion)
- A study evaluating CCS1477 for the treatment of relapsed/refractory myeloma patients
- Oxford pre-cancerous disorders study (OxPLoreD)
- A study evaluating S65487 for the treatment of relapsed/refractory myeloma patients
- bb2121 CART-Cells in relapsed/refractory and high-risk myeloma (KarMMa-2)
- Using diffusion weighted MRI to measure myeloma disease burden and bone loss (LOOMIS)
- Exercise in transplant eligible myeloma patients (PERCEPT)
- Venetoclax and dexamethasone in patients with relapsed or refractory myeloma (CANOVA)
- Trial of immunomodulatory therapy in high risk solitary bone plasmacytoma (IDRIS)
- Selinexor with cyclophosphamide and prednisolone in relapsed or refractory multiple myeloma patients (MUK twelve)
- Tanezumab for bone pain in myeloma
- Donor lymphocyte infusion after stem cell transplant in myeloma (ProT4).
- CC-92480 in combination with dexamethasone in relapsed and refractory multiple myeloma
- AZD4573 in relapsed or refractory myeloma
- Ixazomib, pomalidomide and dexamethasone for relapsed and/or refractory myeloma patients
- Observational evaluation of myeloma patients (PREAMBLE)
- Melflufen and dexamethasone in myleoma patients refractory to lenalidomide (OCEAN trial)
- CC-220 (iberdomide) as a monotherapy and in combination with other treatments
- Myeloma XII (ACCoRd)
Trial Title:
A comparison of imaging techniques used to visualise myeloma in the bone marrow
Treatments:
Myeloma stage:
Trial phase:
Summary:
This study will compare two different imaging methods (PET/MRI scan or PET/CT scan). It aims to determine which method is the best way to see where myeloma is most active in newly diagnosed myeloma patients.
Locations:
King's College Hospital, London
Who can enter the study?:
Newly diagnosed myeloma patients who will receive HDT-SCT as their initial treatment.
What's involved?:
Participants will be assessed and treated as usual, except that they will have an additional scan, a PET/MRI scan, as well as each standard PET/CT scan so that the two imaging methods can be compared. The scans will be done before treatment and after induction treatment (anti-myeloma treatment) given to patients before high-dose therapy and stem cell transplantation (HDT-SCT).
Clinical Information
(for Medical Professionals):
This study will compare PET/MRI with PET/CT, in patients with myeloma who will be treated with HDT-SCT.
For more information, click here.
Find out more about Myeloma UK:
Visit www.myeloma.org.uk